Aliases & Classifications for Detrusor Sphincter Dyssynergia

MalaCards integrated aliases for Detrusor Sphincter Dyssynergia:

Name: Detrusor Sphincter Dyssynergia 12 15
Detrusor and Sphincter Dyssynergia 71

External Ids:

Disease Ontology 12 DOID:12145
ICD9CM 34 596.55
SNOMED-CT 67 236655005
UMLS 71 C0341747

Summaries for Detrusor Sphincter Dyssynergia

MalaCards based summary : Detrusor Sphincter Dyssynergia, also known as detrusor and sphincter dyssynergia, is related to low compliance bladder and neurogenic bladder, and has symptoms including dysuria and urgency of micturition. An important gene associated with Detrusor Sphincter Dyssynergia is P2RX3 (Purinergic Receptor P2X 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Platelet homeostasis. The drugs Acetylcholine and incobotulinumtoxinA have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and testes, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Detrusor Sphincter Dyssynergia

Diseases related to Detrusor Sphincter Dyssynergia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 low compliance bladder 31.3 P2RX3 NGF
2 neurogenic bladder 30.8 TRPV1 TAC1 P2RX3 P2RX2 NGF
3 cystitis 30.6 TRPV1 TAC1 P2RX3 NGF
4 constipation 30.5 TRPV1 TAC1 CALCA
5 interstitial cystitis 30.4 TRPV1 TAC1 P2RX3 NGF
6 spinal cord injury 11.1
7 neural tube defects 10.6
8 vesicoureteral reflux 1 10.6
9 hydronephrosis 10.6
10 acute cystitis 10.6
11 quadriplegia 10.5
12 bladder neck obstruction 10.5
13 spinal cord disease 10.5
14 prostatic hypertrophy 10.4
15 bacteriuria 10.4
16 urethral stricture 10.4
17 paraplegia 10.4
18 herpes simplex 10.4
19 mononeuritis of lower limb 10.3 TRPV1 NGF
20 lesion of sciatic nerve 10.3 TRPV1 NGF
21 prurigo nodularis 10.3 TAC1 NGF
22 multiple system atrophy 1 10.3
23 ataxia and polyneuropathy, adult-onset 10.3
24 prostatic hyperplasia, benign 10.3
25 amnestic disorder 10.3
26 diarrhea 10.3
27 urethritis 10.3
28 prostatitis 10.3
29 rectum adenocarcinoma 10.3
30 wernicke encephalopathy 10.3
31 prostatic adenoma 10.3
32 myopathy 10.3
33 urinary tract obstruction 10.3
34 47,xyy 10.3
35 autonomic dysfunction 10.3
36 back pain 10.3
37 encephalopathy 10.3
38 hypertonia 10.3
39 hinman syndrome 10.3
40 punctate epithelial keratoconjunctivitis 10.2 TAC1 NGF
41 dental pulp disease 10.1 TRPV1 TAC1
42 neurogenic arthropathy 10.1 NGF CALCA
43 cough variant asthma 10.1 TRPV1 TAC1 NGF
44 mononeuropathy 10.1 TRPV1 TAC1 NGF
45 urethral syndrome 10.1 TAC1 P2RX3 NGF
46 nerve compression syndrome 10.1 TRPV1 TAC1 NGF
47 carbamazepine allergy 10.1 TAC1 CALCA
48 perianal hematoma 10.1 TAC1 CALCA
49 photokeratitis 10.0 TRPV1 TRPA1
50 aspiration pneumonia 10.0 TRPV1 TAC1

Comorbidity relations with Detrusor Sphincter Dyssynergia via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Detrusor Sphincter Dyssynergia:



Diseases related to Detrusor Sphincter Dyssynergia

Symptoms & Phenotypes for Detrusor Sphincter Dyssynergia

UMLS symptoms related to Detrusor Sphincter Dyssynergia:


dysuria, urgency of micturition

MGI Mouse Phenotypes related to Detrusor Sphincter Dyssynergia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 AADAT ADCYAP1 ADRA1A ATP2B3 NGF P2RX3
2 cardiovascular system MP:0005385 9.76 ADRA1A ATP2B3 NGF P2RX2 P2RX3 SNAP25
3 integument MP:0010771 9.5 ATP2B3 NGF P2RX3 SNAP25 TAC1 TRPA1
4 taste/olfaction MP:0005394 8.8 SNAP25 TRPA1 TRPV1

Drugs & Therapeutics for Detrusor Sphincter Dyssynergia

Drugs for Detrusor Sphincter Dyssynergia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
2 incobotulinumtoxinA Phase 2, Phase 3
3 Cholinergic Agents Phase 3
4 Neurotransmitter Agents Phase 3
5 abobotulinumtoxinA Phase 3
6 Botulinum Toxins, Type A Phase 3
7 Botulinum Toxins Phase 3
8
Darifenacin Approved, Investigational Phase 2 133099-04-4 444031
9 Mitogens Phase 2
10 Muscarinic Antagonists Phase 2
11 Cholinergic Antagonists Phase 2

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Open Label Pilot Study to Treat Women With Chronic Urinary Retention or Voiding Dysfunction Due to a Primary Disorder of Sphincter Relaxation (Fowler's Syndrome) With Outpatient Urethral Injections of Botulinum Toxin A (BoNT-A) Completed NCT02428881 Phase 2, Phase 3 onabotulinumtoxinA
2 Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms Terminated NCT02078895 Phase 3 Botox
3 Clinical Interest of the Temporary Urethral Stent Allium " Bulbar Urethral Stent " in the Treatment of Detrusor Sphincter Dyssynergia Completed NCT02323243 Phase 1, Phase 2
4 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action Completed NCT01682603 Phase 2 Botulinum toxin A
5 A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity Terminated NCT00845338 Phase 2 Darifenacin (BAY79-4998)
6 Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
7 Impact of Activity-Dependent Plasticity on Bladder Function After Pediatric Spinal Cord Injury Unknown status NCT03559036
8 Neuro-urological Outcome After Spinal Cord Injury Completed NCT01297660
9 Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord Completed NCT00221767
10 Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich Recruiting NCT01293110
11 Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicenter, Randomised, Sham-controlled, Double-blind Clinical Trial Recruiting NCT04315142
12 Functional Mapping With Lumbosacral Epidural Stimulation for Restoration of Bladder Function After Spinal Cord Injury Recruiting NCT03452007
13 Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition for Patients With Multiple Sclerosis Recruiting NCT04024085
14 Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction Active, not recruiting NCT02859844

Search NIH Clinical Center for Detrusor Sphincter Dyssynergia

Genetic Tests for Detrusor Sphincter Dyssynergia

Anatomical Context for Detrusor Sphincter Dyssynergia

MalaCards organs/tissues related to Detrusor Sphincter Dyssynergia:

40
Spinal Cord, Prostate, Testes, Brain, Bone, Smooth Muscle, Colon

Publications for Detrusor Sphincter Dyssynergia

Articles related to Detrusor Sphincter Dyssynergia:

(show top 50) (show all 585)
# Title Authors PMID Year
1
Pharmacotherapeutic management of lower urinary tract symptoms. 61
32452702 2020
2
Urethral dysfunction and alterations of nitric oxide mechanisms in streptozotocin-induced diabetic rats with or without low-dose insulin treatment. 61
32165214 2020
3
The influence of bowel management on urodynamic findings in spina bifida children with detrusor overactivity and detrusor sphincter dyssynergia. 61
32376289 2020
4
Is baseline routine renal ultrasound indicated for all MS patients? 61
31611266 2020
5
Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. 61
32367978 2020
6
Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. 61
32410904 2020
7
Early sacral neuromodulation ameliorates urinary bladder function and structure in complete spinal cord injury minipigs. 61
31868966 2020
8
Botulinum toxin therapy in children with neurogenic detrusor overactivity. 61
31905119 2020
9
[Effects of alpha-1A/D adrenoceptor antagonist and phosphodiesterase type 5 inhibitor on bladder remodeling in rats with spinal cord injury]. 61
31902838 2020
10
The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction. 61
31847090 2019
11
Therapeutic effects of inhibition of brain-derived neurotrophic factor on voiding dysfunction in mice with spinal cord injury. 61
31566429 2019
12
Functional MRI in patients with detrusor sphincter dyssynergia: Is the neural circuit affected? 61
31396992 2019
13
The impact of bowel management on the quality of life in children with spina bifida with overactive bladder and detrusor sphincter dyssynergia. 61
31202611 2019
14
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. 61
31614473 2019
15
Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. 61
30284350 2019
16
The Spectrum of Clinical and Urodynamic Findings in Patients with Spinal Tuberculosis Exhibiting Lower Urinary Tract Symptoms, before and after Spinal Surgical Intervention with Antitubercular Treatment: A Prospective Study. 61
30909676 2019
17
The Description of Urodynamic Study for Bladder Dysfunction in Compressive Myelo- or Radiculo-pathy: A Prospective Study in an Institutional Setup. 61
31497109 2019
18
Time-Dependent Changes of Urethral Function in Diabetes Mellitus: A Review. 61
31260608 2019
19
Anti-Nogo-A Antibodies As a Potential Causal Therapy for Lower Urinary Tract Dysfunction after Spinal Cord Injury. 61
30902870 2019
20
Urine retention in cattle putatively associated with injection of an ivermectin and closantel anthelmintic formulation into the ischiorectal fossa. 61
30742780 2019
21
A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder. 61
30138720 2019
22
Bladder Neuromodulation in Acute Spinal Cord Injury via Transcutaneous Tibial Nerve Stimulation: Cystometrogram and Autonomic Nervous System Evidence From a Randomized Control Pilot Trial. 61
30837835 2019
23
Impact of bowel management in alleviating symptoms of urinary incontinence in patients with spina bifida associated with overactive bladder and detrusor sphincter dyssynergia. 61
29802783 2019
24
Nocturia in Patients With Multiple Sclerosis. 61
31768133 2019
25
Rationales for a Urodynamic Study in Patients with Cervical Spondylotic Myelopathy. 61
30583129 2018
26
Urethral Pressure Measurement as a Tool for the Urodynamic Diagnosis of Detrusor Sphincter Dyssynergia. 61
30599498 2018
27
Targeting p75 neurotrophin receptors ameliorates spinal cord injury-induced detrusor sphincter dyssynergia in mice. 61
29806700 2018
28
The maximum detrusor pressure as a predictive factor of success after sphincterotomy in detrusor-sphincter dyssynergia. 61
30203509 2018
29
Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury. 61
29717510 2018
30
A Proof-of-Concept Study of Transcutaneous Magnetic Spinal Cord Stimulation for Neurogenic Bladder. 61
30135433 2018
31
Detrusor Acontractility after Acute Spinal Cord Injury-Myth or Reality? 61
29352989 2018
32
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. 61
29949878 2018
33
Age-associated urethral dysfunction in urethane-anesthetized rats. 61
29333618 2018
34
Preserved Adrenal Function After Lumbar Spinal Cord Transection Augments Low Pressure Bladder Activity in the Rat. 61
30233411 2018
35
Botulinum Toxin Use in Neurourology. 61
30288145 2018
36
Non-invasive Neuromodulation of Spinal Cord Restores Lower Urinary Tract Function After Paralysis. 61
30008661 2018
37
ICS Educational Module: Electromyography in the assessment and therapy of lower urinary tract dysfunction in adults. 61
28419532 2018
38
Can hydrophilic coated catheters be beneficial for the public healthcare system in Brazil? - A cost-effectiveness analysis in patients with spinal cord injuries. 61
28792195 2018
39
Urinary Disorders and Marfan Syndrome: A Series of 4 Cases. 61
29176310 2018
40
Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. 61
28965354 2018
41
Lower Urinary Tract Function in Familial Spastic Paraplegia. 61
30391939 2018
42
Diagnosis and clinical evaluation of neurogenic bladder. 61
29072046 2017
43
Is urodynamic evaluation a must in all operated cases of open neural tube defects. 61
28576414 2017
44
Early postnatal bladder function in fetoscopic myelomeningocele repair patients. 61
29125525 2017
45
Spinal Transection Alters External Urethral Sphincter Activity during Spontaneous Voiding in Freely Moving Rats. 61
28467736 2017
46
Role of body mass index in school-aged children with lower urinary tract dysfunction: Does weight classification predict treatment outcome? 61
28483466 2017
47
Renal deterioration after spinal cord injury is associated with length of detrusor contractions during cystometry-A study with a median of 41 years follow-up. 61
27813141 2017
48
Chronic Urinary Retention in Multiple Sclerosis Patients: Physiology, Systematic Review of Urodynamic Data, and Recommendations for Care. 61
28716323 2017
49
Effect of urethral wall injection of replication-defective herpes simplex virus-mediated gene transfer of kynurenine aminotransferase on urethral pressure in spinal cord-injured rats. 61
27391207 2017
50
Use of botulinum toxin for voiding dysfunction. 61
28540231 2017

Variations for Detrusor Sphincter Dyssynergia

Expression for Detrusor Sphincter Dyssynergia

Search GEO for disease gene expression data for Detrusor Sphincter Dyssynergia.

Pathways for Detrusor Sphincter Dyssynergia

GO Terms for Detrusor Sphincter Dyssynergia

Cellular components related to Detrusor Sphincter Dyssynergia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.65 TRPV1 SNAP25 P2RX3 CALCA ADCYAP1
2 postsynapse GO:0098794 9.58 SNAP25 P2RX3 P2RX2
3 neuronal cell body GO:0043025 9.55 TRPV1 TAC1 P2RX3 P2RX2 CALCA
4 terminal bouton GO:0043195 9.5 P2RX3 CALCA ADCYAP1
5 integral component of nuclear inner membrane GO:0005639 9.37 P2RX3 P2RX2
6 axon GO:0030424 9.35 TAC1 SNAP25 P2RX3 NGF CALCA
7 cell GO:0005623 9.28 TRPV1 TRPA1 TAC1 P2RX3 P2RX2 CALCA

Biological processes related to Detrusor Sphincter Dyssynergia according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.97 TRPV1 TRPA1 P2RX3 P2RX2 ATP2B3
2 ion transmembrane transport GO:0034220 9.86 TRPV1 TRPA1 P2RX3 ATP2B3
3 chemical synaptic transmission GO:0007268 9.84 TAC1 SNAP25 P2RX3 P2RX2
4 calcium ion transport GO:0006816 9.82 TRPV1 TRPA1 ATP2B3
5 calcium ion transmembrane transport GO:0070588 9.81 TRPV1 TRPA1 ATP2B3
6 cell-cell signaling GO:0007267 9.81 TAC1 CALCA ADRA1A ADCYAP1
7 neuropeptide signaling pathway GO:0007218 9.78 TAC1 CALCA ADCYAP1
8 response to organic substance GO:0010033 9.74 TRPA1 P2RX3 P2RX2
9 excitatory postsynaptic potential GO:0060079 9.67 TRPV1 P2RX3 P2RX2
10 response to cold GO:0009409 9.66 TRPA1 P2RX3
11 neuromuscular synaptic transmission GO:0007274 9.66 P2RX3 P2RX2
12 associative learning GO:0008306 9.65 TAC1 SNAP25
13 glutamate secretion GO:0014047 9.65 TRPV1 SNAP25
14 positive regulation of blood vessel diameter GO:0097755 9.65 CALCA ADCYAP1
15 response to ATP GO:0033198 9.64 P2RX3 P2RX2
16 cellular response to ATP GO:0071318 9.63 TRPV1 P2RX3
17 response to heat GO:0009408 9.63 TRPV1 P2RX3 CALCA
18 positive regulation of calcium-mediated signaling GO:0050850 9.62 P2RX3 P2RX2
19 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.62 TRPV1 CALCA
20 response to carbohydrate GO:0009743 9.61 P2RX3 P2RX2
21 positive regulation of synaptic transmission, GABAergic GO:0032230 9.6 TAC1 ADRA1A
22 positive regulation of calcium ion transport into cytosol GO:0010524 9.59 P2RX3 P2RX2
23 negative regulation of heart rate GO:0010459 9.58 TRPV1 TAC1
24 sensory perception of pain GO:0019233 9.56 TRPV1 TRPA1 TAC1 ADCYAP1
25 peristalsis GO:0030432 9.55 P2RX3 P2RX2
26 positive regulation of cytosolic calcium ion concentration GO:0007204 9.55 TRPV1 TAC1 CALCA ADRA1A ADCYAP1
27 cellular response to nerve growth factor stimulus GO:1990090 9.54 TRPV1 TAC1 CALCA
28 purinergic nucleotide receptor signaling pathway GO:0035590 9.52 P2RX3 P2RX2
29 behavioral response to pain GO:0048266 9.5 TRPV1 P2RX3 P2RX2
30 positive regulation of action potential GO:0045760 9.48 TAC1 ADRA1A
31 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.43 TRPV1 TRPA1
32 thermoception GO:0050955 9.4 TRPV1 TRPA1
33 urinary bladder smooth muscle contraction GO:0014832 9.13 TRPV1 P2RX3 P2RX2
34 response to pain GO:0048265 8.92 TRPV1 TRPA1 TAC1 CALCA

Molecular functions related to Detrusor Sphincter Dyssynergia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ligand-gated ion channel activity GO:0015276 9.32 TRPV1 P2RX2
2 calcium-release channel activity GO:0015278 9.26 TRPV1 TRPA1
3 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX3 P2RX2
4 purinergic nucleotide receptor activity GO:0001614 8.96 P2RX3 P2RX2
5 ion channel activity GO:0005216 8.92 TRPV1 TRPA1 P2RX3 P2RX2

Sources for Detrusor Sphincter Dyssynergia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....